CDSCO Crackdown on Injectable Cosmetics: Why India’s Aesthetics Industry Faces a Major Regulatory Shift

The aesthetics industry in India has grown faster than the rules around it and for years, that gap was commercially exploitable. The consumer paid the price often without knowing it. The CDSCO clarification aims towards closing that gap. The move is overdue and the primary beneficiary is the consumer.

At the heart of this is regulatory arbitrage. A cosmetic in India can move from development to market relatively quickly with minimal compliance obligations, including labelling and formulation details, basic safety standards and no clinical trials required. A drug operates in a completely different world requiring pre-clinical research, toxicology, clinical trials, manufacturing inspections, batch testing, pharmacovigilance and post-market monitoring. Classifying an injectable as a cosmetic lets businesses skip most of that.

When accountability is uneven, the consumer carries the risk and in this case, the risk is not a rash or an allergic reaction. When an injectable procedure goes wrong, the harm is medical, including nerve damage, tissue reactions and lasting scarring. Without approved products, traceable supply chains and accountable practitioners, the consumer has no meaningful right to safety. A person walking into a salon for an injectable procedure has the same right to product safety and accountability as a patient in a hospital. The regulatory arbitrage took that right away quietly. The regulator’s clarification is trying to restore it.

Cosmetics were meant to sit on the skin, to cleanse or beautify from the outside. The moment a product enters the body through an injection, the risk profile changes entirely. It affects muscle activity, collagen production and physiological function, all of which are drug-like outcomes. When something behaves like a drug, it cannot keep being regulated like a beauty cream.

Yet that is exactly what happened. India's two regulatory frameworks, cosmetics under the Cosmetics Rules, 2020 and drugs under the much stricter Drugs and Cosmetics Act, were not designed to overlap. Injectables did not fit cleanly into either box, so the same product got handled under different rules depending on how it was positioned. Some went through the drug pathway, many came in under the cosmetic framework, and many others moved through informal import channels entirely.

The market expanded into this gap. Treatments that earlier sat inside hospitals and qualified dermatology setups spread to clinics, salons, wellness centres and walk-in studios. Social media also accelerated it. Influencer content and bundled packages made injectables feel like routine beauty maintenance. Product authenticity, storage, and practitioner qualifications, among other metrics, varied widely across the chain. India is finally aligning with how the rest of the world treats these products. Under the US FDA framework, Botox is a prescription drug and the European Commission treats cosmetics as products for external application only. CDSCO is closing a gap that most comparable regulators never left open.

The scope of what this clarification touches is wider than it looks. Approvals, imports, manufacturing, sourcing, storage, traceability, practitioner accountability, advertising and adverse-event reporting, the entire chain has to realign. Larger manufacturers already follow most of what the drug pathway demands and will adapt without significant disruption. For smaller manufacturers, the math changes significantly with more regulatory approvals, deeper documentation, stricter manufacturing standards and longer timelines to market, all at a cost structure that was never built to carry them. For smaller clinics, salons and operators outside traditional clinical environments, the reckoning is around sourcing accountability and practitioner qualifications. A clinic that cannot account for where its products came from, or who is qualified to administer them, will find itself exposed.

The practical asks, however, are not complicated. Manufacturers should review their portfolios honestly, if a product is injectable, the working assumption should be that it sits in the drug framework. Clinics should audit sourcing, inventory and practitioner qualifications. Marketers should pull back on language that makes injectables sound routine or risk-free. And consumers should ask basic questions about the product, professionals administering it and what the risks associated with it are, before any procedure.

The clarification is a start. The value will come from implementation, clearer guidelines, stronger enforcement against unapproved products and continued alignment with global practices. The aesthetics market is not going to shrink. The job is to make sure it grows on safety and accountability rather than on the gap the regulator just closed.

(Rishi Agrawal is CEO and CO-Founder of Teamlease Regtech. Views expressed are personal and not necessarily of Openthemagazine.com)